IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout

TheFly reported connected April 14 that Wedbush Securities accrued its terms people connected IDYA from $52 to $58 portion maintaining an Outperform rating. The update followed the company’s merchandise of top-line results from its Phase 2/3 OptimUM-02 objective trial. Management reported that information outcomes stay accordant with earlier studies, with adverse events mostly manageable. The steadfast besides noted that further elaborate findings from the survey are expected to beryllium shared astatine a large aesculapian league successful 2026, which could supply further clarity connected the program’s objective illustration and aboriginal improvement potential.

Adding to the company’s operational momentum, connected April 6, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) reported that it has begun diligent enrollment successful a Phase 1 dose-escalation survey of IDE574, a first-in-class oral small-molecule therapy designed to inhibit KAT6 and KAT7, 2 epigenetic targets progressive successful crab compartment survival.

The early-stage proceedings volition measure safety, pharmacokinetics, and preliminary anti-tumor enactment arsenic a monotherapy successful patients with precocious coagulated tumors, including breast, prostate, colorectal, and lung cancers. The programme is intended to measure a caller dual-mechanism attack aimed astatine overcoming absorption pathways successful oncology and expanding attraction options successful aggregate high-need crab indications done epigenetic modulation strategies.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is an AI-driven precision oncology institution focused connected synthetic lethality-based crab therapies. It uses instrumentality learning and physics-based cause find to make first-in-class targeted crab treatments guided by molecular diagnostics.

While we admit the imaginable of IDYA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 9 Most Undervalued Healthcare Stocks to Buy Now and 10 Most Undervalued Dow Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey connected Google News.